Abstract
We are currently witnessing a number of significant changes in asthma treatment strategy. The news does not only concern the area of severe asthma, where new biological drugs are being added that precisely target the specified phenotype, but there are also fundamental changes in the approach to the newly designed treatment of mild asthma.
We now have a new document, GINA (Global Initiative for Asthma) 2020, which more or less takes into account a number of GINA conclusions from 2019, which we consider to be revolutionary over the last 30 years. It is also necessary to mention the need for a thorough treatment of asthma during the COVID pandemic in 2020.